Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
IMvoke010: Atezolizumab in locally advanced SCCHN
NCT03452137Phase 3Terminated
- Sponsor
- Roche
- Start
- Apr 2018
- Primary completion
- Sep 2023
- Modality
- Monoclonal Antibodies
- Countries
- 23
01
Overview
A Phase 3 trial of atezolizumab in squamous cell carcinoma of the head and neck (HNSCC), sponsored by Roche. Started Apr 2018; status: terminated.
02
Drugs
atezolizumab
03
Conditions
squamous cell carcinoma of the head and neck (HNSCC)
Beyond the preview
Go deeper on NCT03452137.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03452137.